Who are DE-117 ophthalmic solution high's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ASU, Anelazol Sodium Enteric-coated Tablets, Sensodyne Sensitivity & Gum, Dapsone gel, 5%, Mesalazine plus Lactobacillus casei, intraperitoneal nebulisation of magnesium sulphate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/de-117-ophthalmic-solution-high.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

DE-117 ophthalmic solution high — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DE-117 ophthalmic solution high (DE-117 ophthalmic solution high) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anti-inflammatory agent. Area: Ophthalmology.

phase 2 Anti-inflammatory agent Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

DE-117 ophthalmic solution high (DE-117 ophthalmic solution high) — Santen Pharmaceutical Co., Ltd.. DE-117 ophthalmic solution high is an anti-inflammatory agent.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
DE-117 ophthalmic solution high TARGET	DE-117 ophthalmic solution high	Santen Pharmaceutical Co., Ltd.	phase 2	Anti-inflammatory agent
ASU	ASU	Laboratoires Expanscience S.A.	marketed	Plant-derived anti-inflammatory agent
Anelazol Sodium Enteric-coated Tablets	Anelazol Sodium Enteric-coated Tablets	Xuanzhu Biopharmaceutical Co., Ltd.	marketed	Leukotriene inhibitor / Anti-inflammatory agent	Leukotriene synthesis pathway
Sensodyne Sensitivity & Gum	Sensodyne Sensitivity & Gum	HALEON	marketed	Desensitizing toothpaste with antimicrobial and anti-inflammatory agents	Sensory nerve fibers (potassium nitrate); bacterial cell membranes and gum tissue (stannous compounds)
Dapsone gel, 5%	Dapsone gel, 5%	Vanderbilt University Medical Center	marketed	Sulfone antimicrobial and anti-inflammatory agent	Dihydrofolate reductase; neutrophil function modulation
Mesalazine plus Lactobacillus casei	Mesalazine plus Lactobacillus casei	Hospital Cristo Re	marketed	Anti-inflammatory agent plus probiotic combination
intraperitoneal nebulisation of magnesium sulphate	intraperitoneal nebulisation of magnesium sulphate	B.P. Koirala Institute of Health Sciences	marketed	Mineral supplement / Anti-inflammatory agent	NMDA receptor (indirect antagonism); local anti-inflammatory pathways

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anti-inflammatory agent class)

Santen Pharmaceutical Co., Ltd. · 2 drugs in this class
Santen Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DE-117 ophthalmic solution high — Competitive Intelligence Brief. https://druglandscape.com/ci/de-117-ophthalmic-solution-high. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing